Market Cap 27.48M
Revenue (ttm) 640,000.00
Net Income (ttm) -69.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,921.88%
Debt to Equity Ratio -0.90
Volume 1,844,000
Avg Vol 1,043,866
Day's Range N/A - N/A
Shares Out 30.88M
Stochastic %K 3%
Beta 0.32
Analysts Strong Sell
Price Target $14.60

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 475 238 6837
Address:
555 Long Wharf Drive, 12th Floor, New Haven, United States
JOEYD05
JOEYD05 Aug. 19 at 12:42 PM
$BTAI https://share.google/aimode/ENfcYlRSkS9qzQqk7
1 · Reply
SrTxan
SrTxan Aug. 19 at 10:06 AM
$BTAI Toni blocked me… ohhh, heartbreaking. But just like Ernesto, I have more than one account, so I can still see where that little rat is running around. Same with Rodrigo Sagasta over on Spanish Investing… amazing how many of the same rats suddenly show up whenever it’s time to trash BTAI. 🐀🐀🐀 Meanwhile, in just one week the FINRA short-volume ratio has roughly doubled, hitting 70.42% yesterday. That means roughly 7 out of every 10 shares in FINRA reported volume were marked as short sales. It does not mean all of those became new open short positions, but the level of short marked activity is still pretty spectacular. Profit ratio is now 0.09%. Just numbers, of course. It’ll be interesting to see how much of that short flow actually sticks, who keeps absorbing shares being dumped into an already massively underwater shareholder base, and what happens if the company gives the market anything better than the bankruptcy scenario everyone seems to be pricing in.
1 · Reply
Paxhawig
Paxhawig Aug. 19 at 7:40 AM
$BTAI Chapter 11
0 · Reply
Paxhawig
Paxhawig Aug. 19 at 5:47 AM
$BTAI another drop
0 · Reply
KR33P
KR33P Aug. 18 at 7:20 PM
$BTAI 3 more days till we dont have to resd your guy's predictions when none of you know whats gonna happen
1 · Reply
Paxhawig
Paxhawig Aug. 18 at 6:46 PM
$BTAI Chapter 11
1 · Reply
KR33P
KR33P Aug. 18 at 6:33 PM
$BTAI 1k in... 1.6k shares idgaf about speculation or that 1k 😂😂 let em ride
0 · Reply
BioSpecialOne
BioSpecialOne Aug. 18 at 4:38 PM
$BTAI placed LIMIT order for 0.75$
0 · Reply
BioSpecialOne
BioSpecialOne Aug. 18 at 3:46 PM
$BTAI is no longer a standard PDUFA run-up. The latest 10-Q shows $13.8M cash/restricted cash, $107.2M debt, $18.8M accounts payable and only $182K in Q2 product revenue. Management says liquidity is insufficient beyond August. By Aug. 21, BTAI must sign a lender-approved transaction that repays the debt or provides an acceptable capital solution. A $9.0M deferred payment follows Aug. 31, while the IGALMI at-home PDUFA is Nov. 14. Possible outcomes: a sale, IGALMI licensing/JV with a meaningful upfront, an asset sale, debt restructuring, a heavily dilutive equity raise, or Chapter 11. The filing explicitly says BTAI and its lenders are discussing potential DIP financing if no deal is reached. IGALMI may have strategic value, but common equity gets only what remains after secured debt and other claims. A financing headline is not automatically bullish. Terms matter. At $0.82, this is a binary rescue/restructuring trade, not a clean PDUFA setup. Very tempting to catch the knife here...
0 · Reply
SireThinkalot
SireThinkalot Aug. 18 at 2:29 PM
$BTAI Nice recovery today.. 💎🙌
1 · Reply
Latest News on BTAI
BioXcel Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 6 days ago

BioXcel Therapeutics Quarterly report: Q2 2026


BioXcel Therapeutics reports Q1 EPS (54c), consensus (49c)

2026-05-15T12:03:32.000Z - 3 months ago

BioXcel Therapeutics reports Q1 EPS (54c), consensus (49c)


BioXcel Therapeutics Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Quarterly report: Q1 2026


BioXcel Therapeutics Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Earnings release: Q1 2026


BioXcel Therapeutics Transcript: Investor update

Apr 23, 2026, 2:00 PM EDT - 4 months ago

BioXcel Therapeutics Transcript: Investor update


BioXcel Therapeutics Slides: Investor update

Apr 23, 2026, 2:00 PM EDT - 4 months ago

BioXcel Therapeutics Slides: Investor update


BioXcel Therapeutics enrolls first patients in BXCL501 trial

2026-04-08T11:09:11.000Z - 4 months ago

BioXcel Therapeutics enrolls first patients in BXCL501 trial


BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA

2026-04-01T11:09:26.000Z - 5 months ago

BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA


BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)

2026-03-27T11:20:13.000Z - 5 months ago

BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)


BioXcel Therapeutics Annual report: Q4 2025

Mar 27, 2026, 7:00 AM EDT - 5 months ago

BioXcel Therapeutics Annual report: Q4 2025


BioXcel Therapeutics Earnings release: Q4 2025

Mar 27, 2026, 7:00 AM EDT - 5 months ago

BioXcel Therapeutics Earnings release: Q4 2025


BioXcel price target lowered to $6 from $10 at H.C. Wainwright

2026-03-05T13:59:23.000Z - 5 months ago

BioXcel price target lowered to $6 from $10 at H.C. Wainwright


BioXcel Therapeutics Transcript: Status update

Feb 27, 2026, 2:00 PM EST - 6 months ago

BioXcel Therapeutics Transcript: Status update


BioXcel Therapeutics submits sNDA to U.S. FDA for Igalmi

2026-01-20T12:06:39.000Z - 7 months ago

BioXcel Therapeutics submits sNDA to U.S. FDA for Igalmi


BioXcel Therapeutics appoints Pavao as acting CCO

2026-01-12T12:21:09.000Z - 7 months ago

BioXcel Therapeutics appoints Pavao as acting CCO


BioXcel Therapeutics Transcript: AGM 2025

Dec 12, 2025, 9:00 AM EST - 8 months ago

BioXcel Therapeutics Transcript: AGM 2025


BioXcel Therapeutics reports Q3 EPS ($2.18), consensus ($1.34)

2025-11-12T12:16:09.000Z - 10 months ago

BioXcel Therapeutics reports Q3 EPS ($2.18), consensus ($1.34)


BioXcel Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

BioXcel Therapeutics Quarterly report: Q3 2025


BioXcel Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

BioXcel Therapeutics Earnings release: Q3 2025


BioXcel Therapeutics Proxy statement: Proxy Filing

Nov 12, 2025, 7:00 AM EST - 10 months ago

BioXcel Therapeutics Proxy statement: Proxy Filing


BioXcel Therapeutics Proxy statement: Proxy Filing

Oct 31, 2025, 8:00 AM EDT - 10 months ago

BioXcel Therapeutics Proxy statement: Proxy Filing


BioXcel Therapeutics regains compliance with Nasdaq

2025-09-18T11:11:17.000Z - 11 months ago

BioXcel Therapeutics regains compliance with Nasdaq


BioXcel Therapeutics Transcript: Study Result

Sep 10, 2025, 2:00 PM EDT - 1 year ago

BioXcel Therapeutics Transcript: Study Result


BioXcel Therapeutics Press release: Study Result

Sep 10, 2025, 2:00 PM EDT - 1 year ago

BioXcel Therapeutics Press release: Study Result


BioXcel Therapeutics Slides: Study Result

Sep 10, 2025, 2:00 PM EDT - 1 year ago

BioXcel Therapeutics Slides: Study Result


BioXcel Therapeutics Transcript: Study Update

Aug 27, 2025, 8:00 AM EDT - 1 year ago

BioXcel Therapeutics Transcript: Study Update


BioXcel Therapeutics Press release: Study Update

Aug 27, 2025, 8:00 AM EDT - 1 year ago

BioXcel Therapeutics Press release: Study Update


BioXcel Therapeutics Slides: Study Update

Aug 27, 2025, 8:00 AM EDT - 1 year ago

BioXcel Therapeutics Slides: Study Update


BioXcel's agitation drug meets main goal in at-home study

Aug 27, 2025, 7:29 AM EDT - 1 year ago

BioXcel's agitation drug meets main goal in at-home study


BioXcel Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Quarterly report: Q2 2025


BioXcel Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Earnings release: Q2 2025


BioXcel Therapeutics Quarterly report: Q1 2025

May 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Quarterly report: Q1 2025


BioXcel Therapeutics Earnings release: Q1 2025

May 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Earnings release: Q1 2025


BioXcel Therapeutics Annual report: Q4 2024

Mar 27, 2025, 10:30 AM EDT - 1 year ago

BioXcel Therapeutics Annual report: Q4 2024


BioXcel Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 10:30 AM EDT - 1 year ago

BioXcel Therapeutics Earnings release: Q4 2024


BioXcel Therapeutics Announces Reverse Stock Split

Feb 6, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces Reverse Stock Split


BioXcel Therapeutics Proxy statement: Proxy Filing

Dec 30, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Proxy statement: Proxy Filing


BioXcel Therapeutics Proxy statement: Proxy Filing

Dec 18, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Proxy statement: Proxy Filing


BioXcel Therapeutics Announces Proposed Public Offering

Nov 21, 2024, 4:47 PM EST - 1 year ago

BioXcel Therapeutics Announces Proposed Public Offering


BioXcel Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

BioXcel Therapeutics Earnings Call Transcript: Q3 2024


BioXcel Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

BioXcel Therapeutics Quarterly report: Q3 2024


BioXcel Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

BioXcel Therapeutics Earnings release: Q3 2024


BioXcel Therapeutics to Present at ThinkEquity Conference

Oct 29, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at ThinkEquity Conference


JOEYD05
JOEYD05 Aug. 19 at 12:42 PM
$BTAI https://share.google/aimode/ENfcYlRSkS9qzQqk7
1 · Reply
SrTxan
SrTxan Aug. 19 at 10:06 AM
$BTAI Toni blocked me… ohhh, heartbreaking. But just like Ernesto, I have more than one account, so I can still see where that little rat is running around. Same with Rodrigo Sagasta over on Spanish Investing… amazing how many of the same rats suddenly show up whenever it’s time to trash BTAI. 🐀🐀🐀 Meanwhile, in just one week the FINRA short-volume ratio has roughly doubled, hitting 70.42% yesterday. That means roughly 7 out of every 10 shares in FINRA reported volume were marked as short sales. It does not mean all of those became new open short positions, but the level of short marked activity is still pretty spectacular. Profit ratio is now 0.09%. Just numbers, of course. It’ll be interesting to see how much of that short flow actually sticks, who keeps absorbing shares being dumped into an already massively underwater shareholder base, and what happens if the company gives the market anything better than the bankruptcy scenario everyone seems to be pricing in.
1 · Reply
Paxhawig
Paxhawig Aug. 19 at 7:40 AM
$BTAI Chapter 11
0 · Reply
Paxhawig
Paxhawig Aug. 19 at 5:47 AM
$BTAI another drop
0 · Reply
KR33P
KR33P Aug. 18 at 7:20 PM
$BTAI 3 more days till we dont have to resd your guy's predictions when none of you know whats gonna happen
1 · Reply
Paxhawig
Paxhawig Aug. 18 at 6:46 PM
$BTAI Chapter 11
1 · Reply
KR33P
KR33P Aug. 18 at 6:33 PM
$BTAI 1k in... 1.6k shares idgaf about speculation or that 1k 😂😂 let em ride
0 · Reply
BioSpecialOne
BioSpecialOne Aug. 18 at 4:38 PM
$BTAI placed LIMIT order for 0.75$
0 · Reply
BioSpecialOne
BioSpecialOne Aug. 18 at 3:46 PM
$BTAI is no longer a standard PDUFA run-up. The latest 10-Q shows $13.8M cash/restricted cash, $107.2M debt, $18.8M accounts payable and only $182K in Q2 product revenue. Management says liquidity is insufficient beyond August. By Aug. 21, BTAI must sign a lender-approved transaction that repays the debt or provides an acceptable capital solution. A $9.0M deferred payment follows Aug. 31, while the IGALMI at-home PDUFA is Nov. 14. Possible outcomes: a sale, IGALMI licensing/JV with a meaningful upfront, an asset sale, debt restructuring, a heavily dilutive equity raise, or Chapter 11. The filing explicitly says BTAI and its lenders are discussing potential DIP financing if no deal is reached. IGALMI may have strategic value, but common equity gets only what remains after secured debt and other claims. A financing headline is not automatically bullish. Terms matter. At $0.82, this is a binary rescue/restructuring trade, not a clean PDUFA setup. Very tempting to catch the knife here...
0 · Reply
SireThinkalot
SireThinkalot Aug. 18 at 2:29 PM
$BTAI Nice recovery today.. 💎🙌
1 · Reply
Tonyboner
Tonyboner Aug. 18 at 12:30 PM
$BTAI Here is what will happen, they will pay down the debt with the cash they have followed by a raise for cash burn, anyone ever question what they burn 3 million a month on?
1 · Reply
Paxhawig
Paxhawig Aug. 18 at 12:13 PM
$BTAI wolfspeed 2.0?
0 · Reply
SrTxan
SrTxan Aug. 18 at 10:09 AM
$BTAI Ernesto bro, maybe Armistice sold everything, but they still have 6M warrants at $1.60. They’re like rats: they sold all their shares to stay under the radar through warrants, but with a 4.99% ownership cap so they don’t have to disclose. Just like Murchinson did: they sold all their shares but still hold 1.7 million warrants at $4.20. So maybe your POD is going to have to move, just like Toni, who never stops talking shit in this forum and, what a coincidence, disappeared from OTLK once their drug was approved. I’m still here buying the dip, so it actually works for me if you keep talking shit here. So keep playing. You say you made millions shorting BTAI, and I’m going to sell mine at a much higher price. And when that happens, I’ll remind you. I added more shares today, and if it hits new lows, I already have another buy order waiting. Because the useless CEO we have lets you play this game, but soon all the cards will be on the table. Gewinn im Sack, Tschüss zum Pack! Küsschen!
1 · Reply
Babilon1210
Babilon1210 Aug. 18 at 10:08 AM
$BTAI Jesus Im in
0 · Reply
Paxhawig
Paxhawig Aug. 18 at 9:24 AM
$BTAI aemistice sold out
1 · Reply
Tatar2r
Tatar2r Aug. 18 at 9:12 AM
$BTAI Ok, - Armistice cut their stake from 1.91M to 1.62M shares, but - Oaktree bought 1.4 M shares, - Vanguard bought 0.7 M shares, - and a number of other institutionals also increased/opened new positions
1 · Reply
Tonyboner
Tonyboner Aug. 18 at 8:17 AM
$BTAI Down 10c pre market in the am, someone know something.
0 · Reply
Tonyboner
Tonyboner Aug. 18 at 7:11 AM
$BTAI They need money and need it now ! They either raise or fold the company.
0 · Reply
Paxhawig
Paxhawig Aug. 18 at 6:48 AM
$BTAI My Conclusion In terms of content, the filing is less a “normal update” and more of a survival announcement. The real question is not whether BioXcel has a product candidate, but whether the company can stabilize its financing by the deadline without significantly diluting shareholders or necessitating a restructuring.
1 · Reply
fosback11
fosback11 Aug. 17 at 9:45 PM
$BTAI From 10Q, dropped late on Friday. “We currently have no commitments to engage in any specific strategic transaction and there can be no assurance that we will be able to complete additional or alternative financings, business development transactions or other strategic alternatives.”. “Management believes that the Company’s cash, cash equivalents and restricted cash of $13.8 million as of June 30, 2026, will allow the Company to fund its operations and meet its liquidity requirements through the end of August 2026.”
0 · Reply
Babilon1210
Babilon1210 Aug. 17 at 7:32 PM
$BTAI Any understanding on this drop?
1 · Reply
Paulbpaulb
Paulbpaulb Aug. 17 at 5:00 PM
$BTAI “cautiously optimistic” phrase of the day
0 · Reply